Subject of the day
JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $94.19B | +2.7% | |
| Gross profit | $63.94B | +2.5% | |
| Operating income | $21.59B | +6.8% | |
| Net income | $26.80B | +19.1% | |
| Cash from ops | $22.79B | +2.6% |
$262.08
▲ +1.22 (+0.5%)
| 52w hi | $267.24 |
|---|---|
| 52w lo | $170.17 |
| Vol | 3.33M |
| As of | Aug 13 |
Our score +0.45
| Short | +0.35 |
|---|---|
| Medium | +0.60 |
| Long | +0.37 |
computed 2026-08-12
Johnson & Johnson
Healthcare · Drug Manufacturers - General
| Market cap | $631.59B |
|---|---|
| Enterprise value | $656.92B |
| Trailing P/E | 30.44x |
| Forward P/E | 21.29x |
| EV / EBITDA | 18.84x |
| P / S (ttm) | 6.45x |
| Profit margin | 21.5% |
| Return on equity | 25.7% |
| Revenue growth | +6.6% |
| Earnings growth | -0.9% |
| Debt / equity | 57.71 |
| Beta vs SPX | -0.03 |
|---|---|
| Corr SPX | -0.02 |
| Annual vol | 18.8% |
| Annual ret | +26.4% |
| Sharpe | 1.41 |
| Max DD | -15.1% |
Window: 504 trading days (504 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.19 | |
| Sector | +0.12 | |
| Technical | +0.26 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-08-12
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Aug 13 | $261.73 | $262.58 | $259.65 | $262.08 | 3.33M |
| Aug 12 | $256.00 | $261.41 | $255.26 | $260.86 | 4.63M |
| Aug 11 | $261.23 | $264.15 | $258.36 | $259.80 | 5.95M |
| Aug 10 | $259.06 | $262.00 | $258.55 | $261.81 | 8.99M |
| Aug 7 | $255.89 | $259.60 | $255.12 | $259.24 | 6.53M |